Posted by Michael Wonder on 31 Oct 2019
Insurance, pharma figures spar over drug price legislation’s innovation impact
30 October 2019 - Pharmaceutical and health insurance industry representatives on Wednesday sparred over the potential impacts of legislation to lower drug prices, underscoring an emerging flashpoint here as Congress attempts to broker sweeping pharmaceutical industry reforms.
The debate centred on a recent analysis showing Democrats’ signature drug pricing legislation would reduce the number of new drugs approved in the U.S. by eight to 15 in the coming decade.
